KBC Group NV Has $157,000 Position in Haemonetics Co. (NYSE:HAE)

KBC Group NV raised its stake in shares of Haemonetics Co. (NYSE:HAE) by 54.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,016 shares of the medical instruments supplier’s stock after purchasing an additional 712 shares during the period. KBC Group NV’s holdings in Haemonetics were worth $157,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP grew its stake in Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after buying an additional 363,702 shares during the last quarter. Royce & Associates LP boosted its holdings in Haemonetics by 2.6% during the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after acquiring an additional 30,868 shares during the period. Geode Capital Management LLC grew its position in shares of Haemonetics by 1.8% in the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after purchasing an additional 21,547 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares during the period. Finally, Westfield Capital Management Co. LP lifted its position in shares of Haemonetics by 10.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after purchasing an additional 80,783 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on HAE. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research report on Tuesday, December 3rd. Barrington Research reissued an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a report on Wednesday, December 4th. Finally, Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Stock Down 11.6 %

Shares of HAE opened at $62.95 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The company has a 50-day moving average price of $77.44 and a two-hundred day moving average price of $78.73. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 1.07 and a beta of 0.39. Haemonetics Co. has a 12 month low of $61.43 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Equities analysts predict that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.